151 related articles for article (PubMed ID: 36064229)
1. Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells.
Zhao L; Zhang S; Chen H; Kroemer G; Kepp O; Liu P
Methods Cell Biol; 2022; 172():99-114. PubMed ID: 36064229
[TBL] [Abstract][Full Text] [Related]
2. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis.
Kepp O; Liu P; Zhao L; Plo I; Kroemer G
Oncoimmunology; 2020 Jul; 9(1):1792037. PubMed ID: 32923154
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppression by Mutated Calreticulin Released from Malignant Cells.
Liu P; Zhao L; Loos F; Marty C; Xie W; Martins I; Lachkar S; Qu B; Waeckel-Énée E; Plo I; Vainchenker W; Perez F; Rodriguez D; López-Otin C; van Endert P; Zitvogel L; Kepp O; Kroemer G
Mol Cell; 2020 Feb; 77(4):748-760.e9. PubMed ID: 31785928
[TBL] [Abstract][Full Text] [Related]
4. Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells.
Liu X; Sun N; Dong Y; Li J; Liu Y; Ren Y; Yang C; Zhang L; Zhou Y; Tong Z; Ding J; Zhao X; Liu Y; He R; Xu K; Wu Y; Huang Y; Wang H; Tao X; Liu Y
Int Immunopharmacol; 2015 Apr; 25(2):416-24. PubMed ID: 25704851
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of calreticulin exposure associated with immunogenic cell death.
Liu P; Zhao L; Kepp O; Kroemer G
Methods Enzymol; 2020; 632():1-13. PubMed ID: 32000891
[TBL] [Abstract][Full Text] [Related]
6. Calreticulin and cancer.
Fucikova J; Spisek R; Kroemer G; Galluzzi L
Cell Res; 2021 Jan; 31(1):5-16. PubMed ID: 32733014
[TBL] [Abstract][Full Text] [Related]
7. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
[TBL] [Abstract][Full Text] [Related]
8. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
[TBL] [Abstract][Full Text] [Related]
9. Consensus guidelines for the detection of immunogenic cell death.
Kepp O; Senovilla L; Vitale I; Vacchelli E; Adjemian S; Agostinis P; Apetoh L; Aranda F; Barnaba V; Bloy N; Bracci L; Breckpot K; Brough D; Buqué A; Castro MG; Cirone M; Colombo MI; Cremer I; Demaria S; Dini L; Eliopoulos AG; Faggioni A; Formenti SC; Fučíková J; Gabriele L; Gaipl US; Galon J; Garg A; Ghiringhelli F; Giese NA; Guo ZS; Hemminki A; Herrmann M; Hodge JW; Holdenrieder S; Honeychurch J; Hu HM; Huang X; Illidge TM; Kono K; Korbelik M; Krysko DV; Loi S; Lowenstein PR; Lugli E; Ma Y; Madeo F; Manfredi AA; Martins I; Mavilio D; Menger L; Merendino N; Michaud M; Mignot G; Mossman KL; Multhoff G; Oehler R; Palombo F; Panaretakis T; Pol J; Proietti E; Ricci JE; Riganti C; Rovere-Querini P; Rubartelli A; Sistigu A; Smyth MJ; Sonnemann J; Spisek R; Stagg J; Sukkurwala AQ; Tartour E; Thorburn A; Thorne SH; Vandenabeele P; Velotti F; Workenhe ST; Yang H; Zong WX; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Oct; 3(9):e955691. PubMed ID: 25941621
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives.
Aria H; Rezaei M
Biomed Pharmacother; 2023 May; 161():114503. PubMed ID: 36921539
[TBL] [Abstract][Full Text] [Related]
11. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.
Garg AD; Dudek AM; Ferreira GB; Verfaillie T; Vandenabeele P; Krysko DV; Mathieu C; Agostinis P
Autophagy; 2013 Sep; 9(9):1292-307. PubMed ID: 23800749
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic cell death in cancer therapy: Present and emerging inducers.
Zhou J; Wang G; Chen Y; Wang H; Hua Y; Cai Z
J Cell Mol Med; 2019 Aug; 23(8):4854-4865. PubMed ID: 31210425
[TBL] [Abstract][Full Text] [Related]
13. Secreted calreticulin mutants subvert anticancer immunosurveillance.
Liu P; Zhao L; Kroemer G; Kepp O
Oncoimmunology; 2020; 9(1):1708126. PubMed ID: 32002304
[TBL] [Abstract][Full Text] [Related]
14. Calreticulin-Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients.
Kielbik M; Szulc-Kielbik I; Klink M
Cells; 2021 Jan; 10(1):. PubMed ID: 33440842
[TBL] [Abstract][Full Text] [Related]
15. eIF2α phosphorylation is pathognomonic for immunogenic cell death.
Bezu L; Sauvat A; Humeau J; Gomes-da-Silva LC; Iribarren K; Forveille S; Garcia P; Zhao L; Liu P; Zitvogel L; Senovilla L; Kepp O; Kroemer G
Cell Death Differ; 2018 Aug; 25(8):1375-1393. PubMed ID: 29358668
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients.
Kasikova L; Hensler M; Truxova I; Skapa P; Laco J; Belicova L; Praznovec I; Vosahlikova S; Halaska MJ; Brtnicky T; Rob L; Presl J; Kostun J; Cremer I; Ryska A; Kroemer G; Galluzzi L; Spisek R; Fucikova J
J Immunother Cancer; 2019 Nov; 7(1):312. PubMed ID: 31747968
[TBL] [Abstract][Full Text] [Related]
17. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Garg AD; Elsen S; Krysko DV; Vandenabeele P; de Witte P; Agostinis P
Oncotarget; 2015 Sep; 6(29):26841-60. PubMed ID: 26314964
[TBL] [Abstract][Full Text] [Related]
18. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla G; Radecke C; Frentsch M; Walther W; Stintzing S; Riess H; Bullinger L; Na IK
Oncoimmunology; 2022; 11(1):2068109. PubMed ID: 35496500
[TBL] [Abstract][Full Text] [Related]
19. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.
Inoue H; Tani K
Cell Death Differ; 2014 Jan; 21(1):39-49. PubMed ID: 23832118
[TBL] [Abstract][Full Text] [Related]
20. Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner.
Yang PM; Hsieh YY; Du JL; Yen SC; Hung CF
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
